GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lineage Cell Therapeutics Inc (AMEX:LCTX) » Definitions » Price-to-Tangible-Book

LCTX (Lineage Cell Therapeutics) Price-to-Tangible-Book : 10.83 (As of Dec. 12, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Lineage Cell Therapeutics Price-to-Tangible-Book?

As of today (2024-12-12), Lineage Cell Therapeutics's share price is $0.52. Lineage Cell Therapeutics's Tangible Book per Share of Sep. 2024 for the quarter that ended in Sep. 2024 was $0.05. Hence, Lineage Cell Therapeutics's Price to Tangible Book Ratio of today is 10.83.

The historical rank and industry rank for Lineage Cell Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

LCTX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.27   Med: 3.82   Max: 31.14
Current: 10.4

During the past 13 years, Lineage Cell Therapeutics's highest Price to Tangible Book Ratio was 31.14. The lowest was 1.27. And the median was 3.82.

LCTX's Price-to-Tangible-Book is ranked worse than
88.61% of 1203 companies
in the Biotechnology industry
Industry Median: 2.93 vs LCTX: 10.40

A closely related ratio is called PB Ratio. As of today, Lineage Cell Therapeutics's share price is $0.52. Lineage Cell Therapeutics's Book Value per Sharefor the quarter that ended in Sep. 2024 was $0.35. Hence, Lineage Cell Therapeutics's P/B Ratio of today is 1.49.


Lineage Cell Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Lineage Cell Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lineage Cell Therapeutics Price-to-Tangible-Book Chart

Lineage Cell Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.47 7.01 11.95 12.45 31.14

Lineage Cell Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.03 31.14 18.50 16.90 18.86

Competitive Comparison of Lineage Cell Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Lineage Cell Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lineage Cell Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Lineage Cell Therapeutics's Price-to-Tangible-Book falls into.



Lineage Cell Therapeutics Price-to-Tangible-Book Calculation

Lineage Cell Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Sep. 2024 )
=0.52/0.048
=10.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Lineage Cell Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Lineage Cell Therapeutics Business Description

Traded in Other Exchanges
Address
2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Executives
Jill Ann Howe officer: Chief Financial Officer C/O DTX PHARMA, INC., 10655 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO CA 92121
Samuel George A. Iii officer: General Counsel/Secretary C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Michael H. Mulroy director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92807
Brian M Culley director, officer: President and CEO 6725 MESA RIDGE ROAD, SUITE 100, SAN DIEGO CA 92121
Don M Bailey director 1300 N. KELLOGG DRIVE, SUITE D, ANAHEIM CA 92607
Broadwood Partners Lp 10 percent owner BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019
Anula Jayasuriya director 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Dipti Amin director C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Gary S. Hogge officer: SVP,Clinical & Medical Affairs 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kevin Leon Cook officer: Chief Financial Officer C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Alexandra Hernandez officer: Sr Director Finance/Controller C/O LINEAGE CELL THERAPEUTICS, INC., 2173 SALK AVENUE, SUITE 200, CARLSBAD CA 92008
Brandi Roberts officer: CFO & SVP, Finance 12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Chase C. Leavitt officer: General Counsel/Secretary 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501
Edward Wirth officer: Chief Medical Officer C/O INVIVO THERAPEUTICS HOLDING CORP., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142